[
    [
        {
            "time": "",
            "original_text": "智通每日大行研报丨欧舒丹(00973)获里昂看高至36.6港元 大和首予微盟集团(02013)“买入”评级",
            "features": {
                "keywords": [
                    "欧舒丹",
                    "里昂",
                    "36.6港元",
                    "大和",
                    "微盟集团",
                    "买入评级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "消费品",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智通每日大行研报丨欧舒丹(00973)获里昂看高至36.6港元 大和首予微盟集团(02013)“买入”评级",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "瑞信：维持上海医药(02607)“中性”评级 目标价降至15港元 机构下调估值",
            "features": {
                "keywords": [
                    "瑞信",
                    "上海医药",
                    "中性评级",
                    "目标价降至15港元",
                    "机构下调估值"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "瑞信：维持上海医药(02607)“中性”评级 目标价降至15港元 机构下调估值",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "上海医药变革：频频产生新交易、走近创新",
            "features": {
                "keywords": [
                    "上海医药",
                    "变革",
                    "新交易",
                    "创新"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药变革：频频产生新交易、走近创新",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]